Literature DB >> 11073227

Northern epilepsy, a new member of the NCL family.

S Ranta1, A E Lehesjoki.   

Abstract

Northern epilepsy, or progressive epilepsy with mental retardation (EPMR), is an autosomal recessive disorder characterized by normal early development, onset of generalized tonic-clonic seizures between the ages of 5 and 10 years, and subsequent progressive mental retardation. The seizures increase in frequency until puberty after which the epileptic activity starts to decline. Mental retardation begins 2-5 years after the onset of seizures and continues through adulthood. Neuropathological findings have shown that EPMR is a new member (CLN8) of the neuronal ceroid lipofuscinosis (NCL) group of neurodegenerative disorders. The CLN8 gene was identified recently. It encodes a 286 amino acid putative transmembrane protein with no homology to previously known proteins. Subsequently, the homologous mouse gene (Cln8) was sequenced and localized to the region of the mouse genome linked to motor neuron degeneration, mouse mnd. Mnd is a naturally occurring mouse mutant with intracellular autofluorescent inclusions similar to those seen in human CLN8. A mutation in mnd mouse DNA was identified, indicating that mnd is a murine model for CLN8.

Entities:  

Mesh:

Year:  2000        PMID: 11073227     DOI: 10.1007/s100720070039

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

Review 1.  Classification and natural history of the neuronal ceroid lipofuscinoses.

Authors:  Jonathan W Mink; Erika F Augustine; Heather R Adams; Frederick J Marshall; Jennifer M Kwon
Journal:  J Child Neurol       Date:  2013-07-09       Impact factor: 1.987

2.  Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.

Authors:  Jill L Wegrzyn; Steven J Bark; Lydiane Funkelstein; Charles Mosier; Angel Yap; Parsa Kazemi-Esfarjani; Albert R La Spada; Christina Sigurdson; Daniel T O'Connor; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

Review 3.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

4.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

5.  Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8.

Authors:  Elyse M Salpeter; Brian C Leonard; Antonio J Lopez; Christopher J Murphy; Sara Thomasy; Denise M Imai; Kristin Grimsrud; K C Kent Lloyd; Jiong Yan; Rossana Sanchez Russo; Suma P Shankar; Ala Moshiri
Journal:  Ann Transl Med       Date:  2021-08

6.  CLN8 Mutations Presenting with a Phenotypic Continuum of Neuronal Ceroid Lipofuscinosis-Literature Review and Case Report.

Authors:  Magdalena Badura-Stronka; Anna Winczewska-Wiktor; Anna Pietrzak; Adam Sebastian Hirschfeld; Tomasz Zemojtel; Katarzyna Wołyńska; Katarzyna Bednarek-Rajewska; Monika Seget-Dubaniewicz; Agnieszka Matheisel; Anna Latos-Bielenska; Barbara Steinborn
Journal:  Genes (Basel)       Date:  2021-06-23       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.